Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
CEMPRA, INC. (MLNT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 04/20/2020 |
8-K
| Bankruptcy or Receivership, Unregistered Sales of Equity Securities, Material Modifications to Rights of Security Holders, Ch... |
| 04/14/2020 |
8-K
| Bankruptcy or Receivership, Regulation FD Disclosure, Financial Statements and Exhibits |
| 02/14/2020 |
8-K
| Quarterly results |
| 01/08/2020 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing |
| 12/27/2019 |
8-K
| Quarterly results |
| 11/06/2019 |
8-K
| Other Events |
| 10/24/2019 |
8-K
| Quarterly results |
| 09/03/2019 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"FORM 8-K",
"Separation and Release Agreement, between Melinta Therapeutics, Inc. and John H. Johnson",
"Melinta Therapeutics Announces Appointment of Jennifer Sanfilippo to Interim Chief Executive Officer and Director MORRISTOWN, N.J., September 3, 2019 - Melinta Therapeutics, Inc. , a commercial-stage company focused on the development and commercialization of novel antibiotics to treat serious bacterial infections, today announced that Jennifer Sanfilippo has been named interim chief executive officer and director, effective August 28, 2019. Prior to this appointment, Ms. Sanfilippo served as senior vice president and general counsel of Melinta. “Jennifer's appointment to interim chief executive officer is the result of a thoughtful succession planning process undertaken by the board of directors. Jennifer is also an ideal addition to Melinta's board of directors and we are pleased that th..." |
|
| 08/09/2019 |
8-K
| Quarterly results |
| 07/16/2019 |
8-K
| Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits |
| 07/01/2019 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits |
| 06/10/2019 |
8-K
| Submission of Matters to a Vote of Security Holders |
| 06/07/2019 |
8-K
| Other Events |
| 05/09/2019 |
8-K
| Quarterly results |
| 03/13/2019 |
8-K
| Quarterly results |
| 02/25/2019 |
8-K
| Quarterly results |
| 02/21/2019 |
8-K
| Quarterly results |
| 02/04/2019 |
8-K
| Quarterly results |
| 01/02/2019 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 12/19/2018 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Ob... |
| 11/19/2018 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits |
| 11/07/2018 |
8-K
| Quarterly results |
| 11/05/2018 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 10/24/2018 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"FORM 8-K",
"Employment Agreement, between Melinta Therapeutics, Inc. and John H. Johnson",
"Side Letter Agreement with Daniel Mark Wechsler",
"Melinta Therapeutics Announces Appointment of John H. Johnson as Interim Chief Executive Officer New Haven, Conn., October 22, 2018 - Melinta Therapeutics, Inc., , a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, announced today that its board of directors has appointed John H. Johnson as interim chief executive officer , effective immediately. Mr. Johnson, a director of Melinta, succeeds Dan Wechsler, who is stepping down from his role as president, CEO and director to pursue other opportunities. The Board and Mr. Wechsler mutually agreed that now is the right time to transition leadership of the Company. “John is an accomplished biopharmaceutical industry leader with more than 20 years of direct expertise in t..." |
|
| 10/05/2018 |
8-K
| Quarterly results |
| 10/02/2018 |
8-K
| Quarterly results |
| 09/27/2018 |
8-K
| Quarterly results |
| 09/19/2018 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"Melinta Therapeutics Names Peter Milligan as Chief Financial Officer SEPTEMBER 18, 2018 NEW HAVEN, Conn., Sept. 18, 2018 — Melinta Therapeutics, Inc. , a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that the company has appointed Peter Milligan as its new Chief Financial Officer, effective immediately. He will succeed current CFO Paul Estrem, who is retiring from Melinta on October 1, 2018. Milligan is an accomplished executive and established corporate leader who brings nearly 30 years of financial leadership experience, with extensive experience in managing all aspects of corporate and operational financial matters, including numerous capital market transactions. “We are excited to have Peter..." |
|
| 08/07/2018 |
8-K
| Quarterly results |
| 06/14/2018 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 05/29/2018 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits|
Docs:
|
"Underwriting Agreement",
"Opinion of Willkie Farr & Gallagher LLP",
"Melinta Therapeutics Announces Proposed Offering of Common Stock NEW HAVEN, Conn., May 21, 2018 - Melinta Therapeutics, Inc. , a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $75,000,000. All of the shares of the common stock to be sold in the offering are to be sold by Melinta. Certain of Melinta's principal and other shareholders and their respective affiliates and associates, as well as certain of Melinta's directors and executive officers, have indicated an interest in purchasing shares of our common stock in the offering at the public offering price with an aggreg...",
"Melinta Therapeutics Announces Pricing of Public Offering of Common Stock NEW HAVEN, Conn., May 23, 2018 - Melinta Therapeutics, Inc. , a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced the pricing of an underwritten public offering of 22,000,000 shares of its common stock at $5.00 per share, before underwriting discounts and commissions. The size of the offering was upsized from $75,000,000 to $110,000,000. In addition, the underwriters have a 30-day option to purchase up to an additional 2,640,000 shares of common stock from Melinta on the same terms and conditions. The offering is expected to close on May 29, 2018, subject to customary closing conditions. Melinta intends to use the net proceeds...",
"Melinta Therapeutics Announces Closing of Underwritten Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Shares of Common Stock NEW HAVEN, Conn., May 29, 2018 - Melinta Therapeutics, Inc. , a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that the underwriters of its recently announced public offering of 22,000,000 shares of its common stock have exercised in full their option purchase an additional 2,640,000 shares. The offering, including the sale of the additional shares, closed on May 29, 2018. Gross proceeds from the offering were $123,200,000, before deducting underwriting discounts and commissions and expenses paid. Melinta intends to use the net proceeds ..." |
|
| 03/27/2018 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits |
| 03/13/2018 |
8-K
| Quarterly results |
| 01/09/2018 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disp...|
Docs:
|
"Registration Rights Agreement, between Melinta Therapeutics, Inc. and The Medicines Company",
"Registration Rights Agreement, between Melinta Therapeutics, Inc. and Deerfield Private Design Fund IV, L.P., Deerfield Private Design Fund III, L.P., and Deerfield Special Situations Fund, L.P",
"Warrant W-1 to purchase shares of common Stock issued to Deerfield Private Design Fund IV, L.P.",
"Warrant W-2 to purchase shares of common Stock issued to Deerfield Private Design Fund III, L.P.",
"Warrant W-3 to purchase shares of common Stock issued to Deerfield Special Situations Fund, L.P.",
"Securities Purchase Agreement, between Melinta Therapeutics, Inc. and Deerfield Private Design Fund IV, L.P., Deerfield Private Design Fund III, L.P., and Deerfield Special Situations Fund, L.P",
"Facility Agreement, by and among Melinta Therapeutics, Inc., the other loan parties thereto, and Cortland Capital Market Services LLC, as Agent",
"Royalty Agreement, between Melinta Therapeutics, Inc. and Deerfield Private Design Fund IV, L.P., Deerfield Private Design Fund III, L.P., and Deerfield Special Situations Fund, L.P",
"Consent of Independent Auditors",
"Melinta Therapeutics Completes Acquisition of The Medicines Company's Infectious Disease Portfolio" |
|
|
|
|